DELL RECONNECTIn partnership with Goodwill Industries®, Dell Reconnect makes it easy for people to recycle computer equipment they no longer need. As we work toward our company goal of keeping 1 billion pounds of e-waste from landfills by 2014, we want to make sure that our customers have the opportunity to recycle their own used technology. Through the Dell Reconnect program, people can bring unwanted computer monitors, desktops, laptops, printers, keyboards and other electronics to any of the nearly 2,500 participating Goodwill locations in the United States and Canada. There, trained staff evaluate the items and determine whether to responsibly recycle or resell them in the store. Not only do people’s donations help make a healthier planet by keeping e-waste from landfills, but Dell Reconnect is also creating job-training opportunities as well as entry-level and skilled green jobs at Goodwill for people in need of work. Finally, every donation helps families to buy the necessities they need at an affordable price.
How DELL is making an impact on pediatric cancer
Every day, doctors, researchers and healthcare organizations are working tirelessly to develop innovative treatments for kids battling cancer. But advanced technology is needed to analyze large volumes of data quickly so that kids can receive treatments faster. Dell believes technology is a critical part of enabling more effective treatment of disease. And we are equipping doctors and researchers with technology that help accelerate cancer treatments for children with Neuroblastoma.
Focusing on one of the most common cancers found in infants
Neuroblastoma strikes approximately one in 100,000 children in the United States each year. The disease produces tumors in a variety of forms that are difficult to treat with a "one-size-fits-all" approach.
At Dell, we specialize in technology that enables us to share high volumes of information across networks and devices. When combined with the expertise of doctors and researchers, new and innovative treatment approaches can be identified for children with Neuroblastoma.
Dell is supporting physicians, researchers and scientists from the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), the Van Andel Research Institute (VARI), and the Translational Genomics Research Institute (TGen) to conduct the first FDA- approved precision medicine clinical trial for pediatric cancer.
Our donated high performance computing systems will enable researchers to quickly analyze each patient’s unique genetic makeup to develop a personalized treatment plan, reducing the time it takes to begin treating a child from months to days.Learn more about Brooke’s story.Dr. Giselle Sholler Dr. Giselle Sholler received her M.S. in Microbiology and Immunology from McGill University and her M.D. from New York Medical College. At Brown University, she performed a residency in pediatrics and a fellowship in pediatric oncology/hematology. Prior to joining VAI, Dr. Sholler most recently worked in the Division of Pediatric Hematology/Oncology and led the Neuroblastoma Laboratory at the University of Vermont. Dr. Sholler joined VAI in 2011 as Co-Director of the Pediatric Oncology Program, Associate Professor in the Center for Cancer Genomics and Quantitative Biology, and Head of the Laboratory of Neuroblastoma Translational Research. She is jointly appointed with the Helen DeVos Children's Hospital as the Haworth Family Director of the Innovative Therapeutics Clinic in the Division of Pediatric Oncology. As well, she is Chair of the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC).